This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2008 Aug;126(8):1161-3.

doi: 10.1001/archophthalmol.2008.1.

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study

Lingkun Kong, Helen A Mintz-Hittner, Rebecca L Penland, Francis L Kretzer, Patricia Chévez-Barrios

PMID: 18695118
DOI: 10.1001/archophthalmol.2008.1

Case Reports

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study

Lingkun Kong et al. Arch Ophthalmol. 2008 Aug.

. 2008 Aug;126(8):1161-3.

doi: 10.1001/archophthalmol.2008.1.

Authors

Lingkun Kong, Helen A Mintz-Hittner, Rebecca L Penland, Francis L Kretzer, Patricia Chévez-Barrios

PMID: 18695118
DOI: 10.1001/archophthalmol.2008.1

No abstract available

PubMed Disclaimer

Similar articles

Off-label use of bevacizumab in retinopathy of prematurity.
Rishi E, Rishi P, Ratra D, Bhende M. Rishi E, et al. Retina. 2009 Feb;29(2):284; author reply 284-5. doi: 10.1097/IAE.0b013e31818a1ee7. Retina. 2009. PMID: 18854784 No abstract available.
Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
Hoang QV, Kiernan DF, Chau FY, Shapiro MJ, Blair MP. Hoang QV, et al. Arch Ophthalmol. 2010 Aug;128(8):1080-1. doi: 10.1001/archophthalmol.2010.145. Arch Ophthalmol. 2010. PMID: 20697016 No abstract available.
Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
Dorta P, Kychenthal A. Dorta P, et al. Retina. 2010 Apr;30(4 Suppl):S24-31. doi: 10.1097/IAE.0b013e3181ca1457. Retina. 2010. PMID: 20224475
[VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM, Helbig H. Oberacher-Velten IM, et al. Klin Monbl Augenheilkd. 2010 Sep;227(9):694-700. doi: 10.1055/s-0029-1245717. Epub 2010 Sep 15. Klin Monbl Augenheilkd. 2010. PMID: 20845249 Review. German.
Bevacizumab (avastin) for the treatment of retinopathy of prematurity.
Beaulieu MJ. Beaulieu MJ. Neonatal Netw. 2012 Jul-Aug;31(4):242-7. Neonatal Netw. 2012. PMID: 22763251 Review. No abstract available.

See all similar articles

Cited by

Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Taher NO, Ghaddaf AA, Al-Ghamdi SA, Homsi JJ, Al-Harbi BJ, Alomari LK, Almarzouki HS. Taher NO, et al. Front Med (Lausanne). 2022 May 9;9:884608. doi: 10.3389/fmed.2022.884608. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35615084 Free PMC article.
A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.
Pertl L, Steinwender G, Mayer C, Hausberger S, Pöschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A. Pertl L, et al. PLoS One. 2015 Jun 17;10(6):e0129383. doi: 10.1371/journal.pone.0129383. eCollection 2015. PLoS One. 2015. PMID: 26083024 Free PMC article.
Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review.
Alzuabi AK, Alshammari OM, Almousa AN, Abouammoh MA. Alzuabi AK, et al. Saudi J Ophthalmol. 2022 Oct 14;36(3):260-269. doi: 10.4103/sjopt.sjopt_12_22. eCollection 2022 Jul-Sep. Saudi J Ophthalmol. 2022. PMID: 36276253 Free PMC article.
Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
Vural A, Ekinci DY, Onur IU, Hergünsel GO, Yiğit FU. Vural A, et al. Int Ophthalmol. 2019 Oct;39(10):2267-2274. doi: 10.1007/s10792-018-01064-7. Epub 2019 Jan 2. Int Ophthalmol. 2019. PMID: 30604251
Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.
Zou Q, Zhu YQ, Zhang FJ, Liu QP. Zou Q, et al. Int J Ophthalmol. 2022 May 18;15(5):753-759. doi: 10.18240/ijo.2022.05.10. eCollection 2022. Int J Ophthalmol. 2022. PMID: 35601165 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

EY10608/EY/NEI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- ClinicalTrials.gov